You can read this report in its original form here. MAPS' total income in FY 91-92 was $28,859.55. The following categories had no expenditures this fiscal year. Public Relations/Ads, Salaries, Grants, …
Doblin RE, Kleiman MA. Marijuana as antiemetic medicine: a survey of oncologists’ experiences and attitudes. J Clin Oncol 1991 Jul;9(7):1314-9. 2002 New York Times Mention of Survey Reed Irvine, …
1.Introduction to the Legal Record of the DEA’s 1984-1988 MDMA Scheduling Hearings DEA Announcement of proposed scheduling of MDMA as a Schedule I Drug, Federal Register, July 27, 1984 2. Before …
MAPS has completed the first double-blind, placebo-controlled study of the therapeutic use of LSD in human beings since the early 1970s. LSD (lysergic acid diethylamide) is a semi-synthetic compound first …
Phase 3 Trials: FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Therapy for PTSD, Agrees on Special Protocol Assessment MAPS’ highest priority project is sponsoring Food and Drug Administration …
See below for information about psychedelic research around the world not sponsored by MAPS. The studies listed here are limited to those in which psychedelics are administered to human subjects. Studies …
MAPS has completed two observational studies of the long-term effects of ibogaine treatment on patients undergoing therapy at independent ibogaine treatment centers in Mexico and New Zealand. Image: Christopher …
MAPS supports research into the safety and effectiveness of ayahuasca-assisted treatment for drug addiction and PTSD. Banisteriopsis caapi We also support conferences, meetings, and publications about …
MAPS has completed the first-ever clinical trial of smoked marijuana for symptoms of posttraumatic stress disorder (PTSD) in veterans of war. MAPS is working to demonstrate the safety and efficacy of smoked …